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The authors wish to make corrections to the article.

The third sentence of the "Patient Disposition and Demographics" subsection within the "Results" section should read:

"For metformin and sulfonylurea, 72% and 74% of patients also had HbA~1c~ assessed at week 52."

The third paragraph of the "Predictive Parameters" subsection within the "Results" section should read:

"The predictive parameters for improvements in HbA~1c~ for week 24, based on the composite unified early-response measure (reduction in HbA~1c~ level of ≥1.0% or HbA~1c~ level of \<7.0%) for metformin were 0.83, 0.81, 0.44, and 0.96; for sulfonylurea, 0.79, 0.94, 0.71, and 0.96; and for insulin glargine, 0.67, 0.89, 0.65, and 0.90."

Within the footnote to Table 5, the optimal early-response measure should be defined as:

"HbA~1c~ reduction of ≥1.0% for sulfonylurea and glargine at week 24 and for sulfonylurea at week 52, HbA~1c~ reduction of ≥0.8% for metformin at week 24, and HbA~1c~ reduction of ≥0.6% for metformin at week 52".

The online version of the original article can be found under doi:10.1007/s13300-015-0119-x.
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